Gemcitabine Intravesical System: A Novel Treatment Option for BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer

Bladder cancer is the sixth most common cancer in the US, affecting more than 84,000 people annually.^1,2 It is significantly more common in men and tends to affect White men more than those of other races.³ The majority of cases occur in individuals over the age of 55 years.³ Approximately 75% of new diagnoses, or about 64,000 annual cases, are non–muscle-invasive bladder cancer (NMIBC).⁴

NMIBC represents a spectrum of disease confined to the bladder’s inner layers (urothelium or lamina propria) and not invading the detrusor muscle.⁵ High-risk NMIBC typically includes high-grade tumors, carcinoma in situ (CIS), multiple or larger tumors, or recurrence.⁵ The standard initial treatment consists of transurethral resection of bladder tumor (TURBT), followed by intravesical therapy with BCG.^4,6 However, a subset of patients relapse or progress, resulting in BCG-unresponsive disease.^4,6 For these patients, radical cystectomy has often been the recommendation, but many patients are ineligible due to comorbidity or age, or decline surgery due to quality of life considerations.^4,6 There has been a significant unmet medical need for effective, bladder-sparing therapies in BCG-unresponsive NMIBC, especially CIS with or without papillary disease.⁴ Current bladder-sparing treatment options include systemic immunotherapy with pembrolizumab (Keytruda; Merck), gene therapy with nadofaragene firadenovec (Adstiladrin; Ferring Pharmaceuticals), or immunomodulatory therapy using nogapendekin alfa inbakicept-pmln (Anktiva; ImmunityBio) plus BCG.^4,7

A New Treatment Modality: Inlexzo

On September 9, 2025, the FDA approved the gemcitabine intravesical system (Inlexzo; Janssen Biotech, Johnson & Johnson) for adult patients with BCG-unresponsive NMIBC with CIS, with or without papillary tumors.^8,9 This includes patients who are ineligible for, or decline, radical cystectomy.^8,9 Previously known as TAR-200, Inlexzo is designed to deliver prolonged, local release of gemcitabine directly into the bladder over time rather than via standard intravesical instillation.^4,8,9,10 The rationale is that prolonged exposure of the bladder lining (urothelium) to gemcitabine may improve drug penetration and increase tumor cell kill, especially in cases where BCG has failed.^4,8,9 By localizing exposure, systemic toxicity is reduced.^4,8,9 Inlexzo is the first FDA-approved drug-releasing intravesical system for this indication.⁹

Inlexzo is copackaged with a sterile urinary catheter and a sterile stylet required for transurethral insertion into the bladder.¹⁰ The system is placed via a transurethral catheter in an in-office procedure without the need for general anesthesia.^9,10 Insert Inlexzo (225 mg of gemcitabine) into the bladder once every 3 weeks for up to 6 months (8 doses), followed by once every 12 weeks for up to 18 months (6 doses) or until persistent or recurrent NMIBC, disease progression, or unacceptable toxicity.¹⁰

Clinical Trial Results and Differentiation From Traditional Gemcitabine

Inlexzo’s approval is supported by trial data from cohort 2 of SunRISe-1 (NCT04640623), an ongoing, phase 2b, parallel cohort, open-label, multicenter study evaluating the safety and efficacy of TAR-200 in patients with BCG-unresponsive high-risk NMIBC who are ineligible for or have elected not to undergo radical cystectomy. ^4,8-10 Cohort 2—Inlexzo monotherapy—studied 83 adult patients with BCG-unresponsive NMIBC, CIS positive/negative papillary disease following transurethral resection, 82% of whom achieved a complete response (CR), indicating no signs of cancer were found after completing treatment.^4,8-10

Strong durability was demonstrated, with 51% of patients maintaining CR at the 1-year mark.^4,8-10 Most treatment-related adverse events were low grade and related to urinary symptoms such as frequency, urgency, dysuria, and urinary tract infections, as well as laboratory abnormalities including decreased hemoglobin, increased lipase, decreased lymphocytes, increased creatinine, increased potassium, increased aspartate aminotransferase, decreased sodium, and increased alanine aminotransferase.^4,8-10 Key findings are summarized in the Table below.

Following TURBT, a single dose of intravesical aqueous gemcitabine has been used off-label for years in NMIBC but shows limited sustained efficacy due to rapid clearance from the bladder.⁴ Evidence supporting the use of off-label gemcitabine in these patients is based on small mixed cohorts, oftentimes retrospective, and demonstrates CR rates ranging from 28% to 47%, with durability seldom greater than a year.⁴ In a meaningful advancement, Inlexzo is differentiated in its continuous delivery of gemcitabine over 3 weeks via a drug-eluting silicone insert, which allows for sustained urothelial exposure and curtails systemic uptake.^4,10 Study results illustrated outcomes not previously seen with conventional off-label use of intravesical gemcitabine, including a significantly greater complete response rate.^4,8-10

The Role of the Pharmacist in Facilitating Treatment With Inlexzo and Implications for Practice

Pharmacists play a pivotal role in supporting the safe and effective use of Inlexzo for adult patients with BCG-unresponsive NMIBC with CIS, with or without papillary tumors. As experts in medication management, they must understand Inlexzo’s novel delivery system and its indication for the treatment of adult patients.

Pharmacists will be involved in formulary decisions, preparation and handling logistics, and ensuring treatment cycles are appropriately scheduled. Inlexzo should be inserted and removed by a trained health care provider. Health care providers should become thoroughly familiar with the insertion and removal instructions before attempting to insert or remove Inlexzo. Though a trained health care provider inserts the device, pharmacy teams are responsible for confirming product availability, understanding dosing intervals, and coordinating care with the clinical team.

Pharmacists should collaborate closely with providers to manage adverse effects and provide supportive care when needed. Educating patients on what to expect from the gemcitabine intravesical system, the insertion process, and the importance of follow-up assessments is essential to support adherence and reduce anxiety.

Pharmacists also help address access and reimbursement challenges, assisting with prior authorizations and connecting patients to support programs. By contributing to shared decision-making and facilitating bladder-preserving care, pharmacists ensure that patients derive the maximum benefit from this innovative therapy. For pharmacists, staying current with evolving guidelines, ensuring safe use, managing adverse effects, educating patients, and supporting multidisciplinary teams will be essential to integrating this new therapy into practice.

Conclusion

The approval of Inlexzo represents more than just a new treatment option—it signals a broader shift toward innovative drug delivery systems that may reshape how certain cancers are managed.^4,8,9 By combining the proven efficacy of gemcitabine with a prolonged-release intravesical platform, Inlexzo addresses a long-standing gap in care for patients.^4,8,9 As the field of uro-oncology continues to evolve, treatments like Inlexzo demonstrate the potential for preserving both the bladder and the patient’s quality of life through precision, patient-centered approaches. Continued collaboration among urologists, oncologists, pharmacists, and patients will be critical to realizing the full benefits of this emerging therapy.

REFERENCES

1. Key statistics for bladder cancer. American Cancer Society. January 13, 2026. Accessed September 25, 2025. https://www.cancer.org/cancer/types/bladder-cancer/about/key-statistics.html

2. Cancer stat facts: bladder cancer. National Cancer Institute. Accessed September 25, 2025. https://seer.cancer.gov/statfacts/html/urinb.html

3. May is Bladder Cancer Awareness Month. American Association for Cancer Research. April 24, 2025. Accessed September 25, 2025. https://www.aacr.org/patients-caregivers/awareness-months/bladder-cancer-awareness

4. Inlexzo (gemcitabine intravesical system) for BCG-unresponsive NMIBC. Rx Brief: Oncology. September 2025. Accessed September 25, 2025. www.ipdanalytics.com

5. What is bladder cancer? National Cancer Institute. February 16, 2023. Accessed September 25, 2025. https://www.cancer.gov/types/bladder

6. Intravesical therapy for bladder cancer. American Cancer Society. Updated September 18, 2025. Accessed September 25, 2025. https://www.cancer.org/cancer/types/bladder-cancer/treating/intravesical-therapy.html

7. Payer and provider insights: biosimilars. IPD Analytics LLC. 2025. Accessed September 25, 2025. https://www.ipdanalytics.com/payer-provider-insights

8. FDA approves gemcitabine intravesical system for non-muscle invasive bladder cancer. FDA. September 9, 2025. Accessed September 25, 2025. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-gemcitabine-intravesical-system-non-muscle-invasive-bladder-cancer

9. U.S. FDA approval of Inlexzo (gemcitabine intravesical system) set to transform how certain bladder cancers are treated. Johnson & Johnson. September 9, 2025. Accessed September 25, 2025. https://www.jnj.com/media-center/press-releases/u-s-fda-approval-of-inlexzo-gemcitabine-intravesical-system-set-to-transform-how-certain-bladder-cancers-are-treated

10. Inlexzo. Prescribing information. Janssen Biotech Inc; 2025. Accessed September 25, 2025. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INLEXZO-pi.pdf